Nightstar Therapeutics PLC (NITE) Expected to Post Earnings of -$0.39 Per Share

Share on StockTwits

Wall Street brokerages expect that Nightstar Therapeutics PLC (NASDAQ:NITE) will post earnings of ($0.39) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Nightstar Therapeutics’ earnings. The highest EPS estimate is ($0.33) and the lowest is ($0.42). The company is expected to announce its next earnings results on Monday, November 12th.

On average, analysts expect that Nightstar Therapeutics will report full year earnings of ($1.62) per share for the current fiscal year, with EPS estimates ranging from ($1.77) to ($1.51). For the next year, analysts expect that the company will post earnings of ($1.52) per share, with EPS estimates ranging from ($1.75) to ($1.38). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that cover Nightstar Therapeutics.

Nightstar Therapeutics (NASDAQ:NITE) last posted its earnings results on Monday, August 13th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.12.

NITE has been the subject of a number of research analyst reports. Chardan Capital reiterated a “buy” rating and issued a $40.00 target price on shares of Nightstar Therapeutics in a research note on Wednesday, June 6th. Mizuho lifted their target price on shares of Nightstar Therapeutics to $24.00 and gave the company a “buy” rating in a research note on Tuesday. Janney Montgomery Scott initiated coverage on shares of Nightstar Therapeutics in a report on Wednesday, August 22nd. They issued a “buy” rating and a $34.00 price target for the company. Zacks Investment Research raised shares of Nightstar Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 9th. Finally, UBS Group lowered shares of Nightstar Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, June 27th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $29.86.

Shares of NASDAQ:NITE traded up $2.20 during trading on Friday, reaching $24.80. The stock had a trading volume of 223,904 shares, compared to its average volume of 76,508. Nightstar Therapeutics has a 52 week low of $10.01 and a 52 week high of $24.93. The stock has a market capitalization of $631.69 million and a P/E ratio of -15.21.

Several institutional investors have recently modified their holdings of NITE. Millennium Management LLC acquired a new stake in shares of Nightstar Therapeutics in the first quarter valued at approximately $507,000. Stanley Laman Group Ltd. acquired a new stake in shares of Nightstar Therapeutics in the second quarter valued at approximately $195,000. Woodford Investment Management Ltd acquired a new stake in shares of Nightstar Therapeutics in the second quarter valued at approximately $5,024,000. Bank of America Corp DE acquired a new stake in shares of Nightstar Therapeutics in the second quarter valued at approximately $132,000. Finally, Redmile Group LLC increased its holdings in shares of Nightstar Therapeutics by 0.9% in the second quarter. Redmile Group LLC now owns 1,785,446 shares of the company’s stock valued at $28,567,000 after purchasing an additional 16,500 shares in the last quarter. 28.62% of the stock is owned by institutional investors and hedge funds.

About Nightstar Therapeutics

Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia.

Featured Story: Average Daily Trade Volume – What You Need to Know

Get a free copy of the Zacks research report on Nightstar Therapeutics (NITE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nightstar Therapeutics (NASDAQ:NITE)

Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply